Practice Parameter for the Use of Fresh-Frozen Plasma, Cryoprecipitate, and Platelets

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 10, 1994, Pages 777-781

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN COFACTOR II; PROTEIN C; PROTHROMBIN; VITAMIN K GROUP; WARFARIN;

ALLOIMMUNIZATION; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CRYOPRECIPITATE; GRAFT VERSUS HOST REACTION; HEALTH CARE QUALITY; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HEMOPHILIA A; HEMOSTASIS; HUMAN; HYPOFIBRINOGENEMIA; LUNG INJURY; OPEN HEART SURGERY; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; VIRUS INFECTION; VON WILLEBRAND DISEASE;

EID: 0028269290     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510340067036     Document Type: Article

References (27)

1. McVay PA, Toy PTCY. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion. 1991;21:164-171.
2. Fresh-frozen plasma: indications and risks. JAMA. 1985;253:551-553. NIH Consensus Conference.
3. Shanberge JN, Quattrochiocchi-Longe T. Analysis of fresh frozen plasma administration with suggestions for ways to reduce usage. Transfus Med. 1992;2:189-194.
4. Leslie SD, Toy PTCY. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid. Am J Clin Pathol. 1991;96:770-773.
5. Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med. 1980;31:509-540.
6. NIH Consensus Conference. Platelet transfusion therapy. JAMA. 1987;257:1777-1780.
7. Gaydos LA, Freireich EF, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905-909.
8. Rodgers RP, Levin IA. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990; 16:1-20.
9. Beutler E. Platelet transfusion: The 20,000/μl trigger. Blood. 1993;81:1411-1413.
10. Heckman K, Weiner GJ, Strauss RG, et al. Randomized evaluation of the optimal platelet count for prophylactic platelet transfusion in patients undergoing induction therapy for acute leukemia. Blood. 1993;82(suppl 1):192a.
11. Gmur J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet. 1991;338: 1223-1226.
12. Goodnough LT, Johnston MFM, Ramsey G, et al. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 1990;50:675-683.
13. Reed R, Ciavarella D, Heimback D, et al. Prophylactic platelet administration during massive transfusion. Ann Surg. 1986;203:40-48.
14. Gordon KI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusion and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol. 1987;27:194-201.
15. Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. 1986;80:1051-1054.
16. Mannucci PM. Desmopressin: a nontransfusion form of treatment for congenital and acquired bleeding disorders. Blood. 1988;72:1449-1455.
17. Galel SA, Grumet FC. Platelet alloimmunization. In: Rossi E, Simon T, Moss G, eds. Principles of Transfusion Medicine. Baltimore, Md: Williams & Wilkins; 1991:271-278.
18. Pool JG, Hershgold EJ, Pappenhagen AB. High potency antihaemophilic factor concentrates prepared from cryoglobulin precipitate. Nature. 1964; 203:312.
19. Hoffman M, Jenner P. Variability in the fibrinogen and von Willebrand factor content of cryoprecipitate. Am J Clin Pathol. 1990;93:694-697.
20. Ness PM, Perkins HA. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA. 1979;241:1690-1691.
21. Mammen EF. Fibrinogen abnormalities. Semin Thromb Hemost. 1983;9:1-9.
22. Holmberg L, Nilsson IM. Von Willebrand' disease. Eur J Haematol. 1992;48:127-141.
23. Berntorp E, Nilsson IM. Use of a high-purity factor VIII concentrate (Humate-P™) [Hemate-P™] in von Willebrand' disease. Vox Sang. 1989; 56:212-217.
24. Green D, Potter EV. Failure of AHF concentrate to control bleeding in von Willebrand' disease. Am J Med. 1976;60:357-360.
25. Mannucci PM, Ruggeri ZM, Pareti FL, Capitanio A. 1-Desamino-8-D-arginine vasopressin: a new pharmacological approach to the management of hemophilia and von Willebrand' disease. Lancet. 1977;1:869-872.
26. Holmberg L, Nilsson IM, Borge I, Gunnarson M, Sjorin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand' disease. N Engl J Med. 1983; 309:816-821.
27. Walker RH. Special report: Transfusion risks. Am J Clin Pathol. 1987;88:374-378.